N/A N=80 Skin Prep to Reduce Postoperative Shoulder Infection
Shoulder Infection
Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=101 Skin and Soft Tissue Infection (SSTI) Study
Skin Diseases, Infectious · Soft Tissue Infections
Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71
N/A N=20 Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
Postoperative Wound Infection Deep Incisional Surgical Site · Prosthesis and Implants · Surgical Site Infection
Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants
Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
N/A N=148 ObservAtional Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers
Skin Cancer
Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 4 N=6,785 Pre-operative Alcohol Skin Solutions in Fractured Extremities
Surgical Site Infection · Unplanned Fracture-Related Reoperation · Open Appendicular Fracture
Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 20; 27; 6; 9 Participants
Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 4 N=1,077 Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Phase 3 N=265 China Registration Study in Patients With Skin Infections
Skin Diseases · Infectious
Primary: Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) — 0.00; 0.01 percentage
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 4 N=70 Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Atopic Dermatitis · Secondary Infection
Primary: Bacteriological Culture — 13; 3; 16; 5 participants
Phase 2 N=150 Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
Infectious Skin Diseases · Bacterial Skin Diseases · Staphylococcal Skin Infections
Primary: Number of Participants With a Clinical Response of Cure — 38; 34; 37 Participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
Phase 2 N=84 GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Infections, Bacterial
Primary: Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE) — 49; 20; 1; 1 Participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Phase 3 N=761 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Phase 3 N=813 Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Abscess · Wound Infection · Diabetic Foot
Primary: Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population — 88.6; 89.6 percentage of…
Phase 3 N=850 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
Phase 3 N=679 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
Phase 2 N=120 MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
Bacterial Infections
Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants
Phase 2 N=28 In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area
Surgical Skin Preparation · Surgical Procedure, Unspecified
Primary: Comparison of Log Change of Skin Flora Relative to Pre-treatment (Baseline) in Each of 3 Sampling Sites at a Defined Post-treatment Sampling Time. — -2.19; -1.85; -2.42…
N/A N=35 Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds
Healthy Volunteers
Primary: Microbial Community Richness - Baseline (Day 0) — 56.5862069; 32.13043478; 43.72413793; 34.03703704 Number of bacterial taxa — p=0.071225
Phase 2 N=256 A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants